Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Comput Biol Med ; 180: 108876, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39089112

RESUMO

Pharmacokinetic/Pharmacodynamic (PK/PD) modeling is crucial in the development of new drugs. However, traditional population-based PK/PD models encounter challenges when modeling for individual patients. We aim to explore the potential of constructing a pharmacodynamic model for individual breast cancer pharmacodynamics leveraging only limited data from early clinical trial phases. While previous studies on Neural Ordinary Differential Equations (ODEs) suggest promising results in clinical trial practices, they primarily focused on theoretical applications or independent PK/PD modeling. PD modeling from complex and irregular clinical trial data, especially when interacting with PK parameters, is still unclear. To achieve that, we introduce a Data-driven Neural Ordinary Differential Equation (DN-ODE) modeling for breast cancer tumor dynamics and progression-free survival data. To validate this approach, experiments are conducted with early-phase clinical trial data from the Amcenestrant (an oral treatment for breast cancer) dataset (AMEERA 1-2), aiming to predict pharmacodynamics in the later phase (AMEERA 3). DN-ODE model achieves RMSE scores of 8.78 and 0.21 in tumor size and progression-free survival, respectively, with R2 scores over 0.9 for each task. Compared to PK/PD methodologies, DN-ODE is able to predict robust individual tumor dynamics with only limited cycle data. We also introduce Principal Component Analysis visualizations for encoder results, demonstrating the DN-ODE's capability to discern individual distributions and diverse tumor growth patterns. Therefore, DN-ODE facilitates comprehensive drug efficacy assessments, pinpoints potential responders, and aids in trial design.


Assuntos
Neoplasias da Mama , Modelos Biológicos , Humanos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Feminino , Intervalo Livre de Progressão , Redes Neurais de Computação , Antineoplásicos/uso terapêutico , Antineoplásicos/farmacocinética
2.
Sensors (Basel) ; 19(19)2019 Sep 23.
Artigo em Inglês | MEDLINE | ID: mdl-31547565

RESUMO

Real-time capturing of vehicle motion is the foundation of connected vehicles (CV) and safe driving. This study develops a novel vehicle motion detection system (VMDS) that detects lane-change, turning, acceleration, and deceleration using mobile sensors, that is, global positioning system (GPS) and inertial ones in real-time. To capture a large amount of real-time vehicle state data from multiple sensors, we develop a dynamic time warping based algorithm combined with principal component analysis (PCA). Further, the designed algorithm is trained and evaluated on both urban roads and highway using an Android platform. The aim of the algorithm is to alert adjacent drivers, especially distracted drivers, of potential crash risks. Our evaluation results based on driving traces, covering over 4000 miles, conclude that VMDS is able to detect lane-change and turning with an average precision over 76% and speed, acceleration, and brake with an average precision over 91% under the given testing data dataset 1 and 4. Finally, the alerting tests are conducted with a simulator vehicle, estimating the effect of alerting back or front vehicle the surrounding vehicles' motion. Nearly two seconds are gained for drivers to make a safe operation. As is expected, with the help of VMDS, distracted driving decreases and driving safety improves.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA